MYC and Miyoshi myopathy: Further studies demonstrate that anlotinib directly interacts with c-Myc, accelerates its ubiquitin proteasome-dependent degradation, followed by genome-wide downregulation of c-Myc-dependent target genes, which contributes to the anti-MM effect of anlotinib.